<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548335" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548335/" /><meta name="ncbi_pagename" content="Ipilimumab - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ipilimumab - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Ipilimumab" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2018/02/16" /><meta name="citation_pmid" content="31643657" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548335/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ipilimumab" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2018/02/16" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548335/" /><meta name="description" content="Ipilimumab is a human monoclonal antibody to cytotoxic T lymphocyte antigen-4 which acts as an immune checkpoint inhibitor increases immune reactivity and is used to treat metastatic malignant melanoma. Ipilimumab has major side effects, many of which can be serious and life threatening including acute liver injury." /><meta name="og:title" content="Ipilimumab" /><meta name="og:type" content="book" /><meta name="og:description" content="Ipilimumab is a human monoclonal antibody to cytotoxic T lymphocyte antigen-4 which acts as an immune checkpoint inhibitor increases immune reactivity and is used to treat metastatic malignant melanoma. Ipilimumab has major side effects, many of which can be serious and life threatening including acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548335/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Ipilimumab/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548335/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C400E0465FB3100000000086E026D.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548335_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548335_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/InterleukinRcptAntag/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ipratropium/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548335_"><span class="title" itemprop="name">Ipilimumab</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 16, 2018</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Ipilimumab.OVERVIEW"><h2 id="_Ipilimumab_OVERVIEW_">OVERVIEW</h2><div id="Ipilimumab.Introduction"><h3>Introduction</h3><p>Ipilimumab is a human monoclonal antibody to cytotoxic T lymphocyte antigen-4 which acts as an immune checkpoint inhibitor increases immune reactivity and is used to treat metastatic malignant melanoma. Ipilimumab has major side effects, many of which can be serious and life threatening including acute liver injury.</p></div><div id="Ipilimumab.Background"><h3>Background</h3><p>Ipilimumab (ip&#x0201d; i lim&#x02019; ue mab) is a human recombinant monoclonal immunoglobulin G1 antibody to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which is used in cancer immunotherapy. The CTLA-4 antigen is an important checkpoint molecule that modulates and down regulates T cell responses. Inhibition of CTLA on the surface of activated T cells prevents its binding to the costimulatory factor B7, which allows for a continued activation and proliferation of T cells. The subsequent enhancement of cytotoxic reactivity may play a beneficial role in cancer immunotherapy and can break immunological tolerance. In several large multicenter studies, ipilimumab therapy resulted in a prolongation of survival in patients with advanced, metastatic or unresectable malignant melanoma, and a proportion of patients had a long term remission. Ipilimumab was approved for use in advanced malignant melanoma in the United States in 2009, the first monoclonal checkpoint inhibitor approved for use in treating neoplastic diseases. Ipilimumab has also been evaluated in several other forms of cancer, including breast, colon, renal cell and pancreatic cancer, alone and in combination with other checkpoint inhibitors such as nivolumab (anti-PD-1). Ipilimumab is available in liquid solution in 50 and 200 mg vials (5 mg/mL) under the brand name Yervoy. The typical regimen is 3 mg/kg as an intravenous infusion every 3 weeks for a total of four doses. Ipililmumab is also approved for adjuvant therapy of melanoma where it is given in higher doses long term. Side effects are common and can be severe, life threatening and even fatal. As many as 70% of treated patients develop immune related side effects as a result of immune enhancement including enterocolitis, dermatitis, endocrinopathy, neuropathy, nephritis and hepatitis. Most of these reactions respond to immunosuppressive therapy. Early recognition and prompt management of these side effects is an integral component of proper use of ipilimumab.</p></div><div id="Ipilimumab.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Mild-to-moderate serum aminotransferase elevations are not uncommon (10% to 50%) during ipilimumab therapy, but are usually self-limited and resolve even with continuing cyclic therapy. Serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations above 5 times the upper limit of normal (ULN) occur in 1% to 5% of patients, and a proportion of these individuals (~1%) develop clinically apparent liver injury that can be severe. The onset of injury is usually after 2 to 4 cycles, 3 to 9 weeks after initiation of treatment. The pattern of enzyme elevation is most frequently hepatocellular, but can be mixed, particularly at the onset of injury. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.liver-histology/">Liver histology</a> demonstrates an acute hepatitis-like pattern with focal or confluent necrosis and prominent lymphocytic infiltrates of activated T cells, which is compatible with an immune mediated hepatic injury. Fibrin ring granulomas have been described in some cases and considered somewhat pathognomic of ipilimumab hepatic immune injury. Despite features of immune-mediated injury, autoantibodies are usually not present. Restarting ipilimumab can result in recurrence of injury, although corticosteroid treatment may block recurrence.</p><p>The effects of anti-CTLA-4 inhibition on hepatitis B have not been reported, as enrollment criteria in the clinical trials of ipilimumab have usually excluded patients with hepatitis B or C or preexisting liver disease. However, it is possible that anti-CTLA-4 treatment would exacerbate chronic hepatitis B and C by enhancing T cell cytotoxicity to viral antigens.</p><p>Likelihood score: A (very likely cause of clinically apparent liver injury).</p></div><div id="Ipilimumab.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of liver injury due to ipilimumab is likely to be immunologically mediated and some cases have appeared to respond to corticosteroid or immunosuppressive therapy, allowing for continuation of ipilimumab therapy.</p></div><div id="Ipilimumab.Outcome_and_Management"><h3>Outcome and Management</h3><p>Guidelines for management of patients receiving ipilimumab recommend monitoring of liver test results before starting therapy and at the time of each infusion. Corticosteroid therapy is recommended for patients who develop serum aminotransferase elevations above 5 times the ULN, initiating therapy with high doses of intravenous methylprednisolone, switching to oral prednisone after 1 to 2 days, and continuing tapering doses for at least 30 days. Most cases of hepatitis due to ipilimumab resolve with prompt institution of immunosuppressive therapy. In some more protracted and resistant instances, adding a second agent to corticosteroids, such as antithymocyte globulin, tacrolimus, azathioprine or mycophenolate mofetil, has resulted in resolution of the injury. The few fatal cases that have been reported occurred in patients who had other severe immune related adverse events (Stevens Johnson syndrome, capillary leak syndrome) or who had a delay in starting corticosteroid therapy. Restarting ipilimumab after severe liver injury requiring corticosteroid therapy is usually promptly followed by recurrence of liver injury and is not recommended.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a>, <a href="/books/n/livertox/MonoclonalAntibodies/">Monoclonal Antibodies</a>, Checkpoint Inhibitors</p></div></div><div id="Ipilimumab.CASE_REPORT"><h2 id="_Ipilimumab_CASE_REPORT_">CASE REPORT</h2><div id="Ipilimumab.Case_1._Clinically_apparent__"><h3>Case 1. Clinically apparent, acute liver injury due to ipilimumab.</h3><p>[Modified from Case 5 in: Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 2012; 57: 2233-40. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22434096" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 43 year old man with metastatic melanoma developed erythema, rash and elevations in serum enzymes 3 days after a third infusion of ipilimumab. He had no history of liver disease, and all liver tests had been normal before starting ipilimumab therapy. Serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> was 173 U/L (4 times ULN) and Alk P 131 (1.1 times ULN), while bilirubin levels were normal. The absolute eosinophil count was raised (889/&#x000b5;L) and antinuclear antibody was reactive (2.4 by ELISA), but smooth muscle antibody was not present, and immunoglobulin levels were normal. Over the next few days, liver tests worsened with ALT rising to 2860 U/L, Alk P 410 U/L and total bilirubin 2.2 mg/dL. A liver biopsy showed an acute hepatitis superimposed upon fatty liver disease with steatosis, slight ballooning degeneration, occasional <a class="def" href="/books/n/livertox/glossary/def-item/glossary.mallory-bodies/">Mallory bodies</a> and slight fibrosis. Initiation of oral prednisone therapy was followed by a slow improvement in enzymes, which fell into the normal range approximately 5 months after onset. Prednisone was later stopped without recurrence of liver injury. He died of progressive metastatic melanoma one year later.</p><div id="Ipilimumab.Key_Points"><h4>Key Points</h4><div id="Ipilimumab.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548335/table/Ipilimumab.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ipilimumab.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Ipilimumab</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Mixed initially (R=3.7), hepatocellular at peak (R=20.2)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">1+ (symptoms and liver enzyme elevations without frank jaundice)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">5 months</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">None mentioned</td></tr></tbody></table></div></div></div><div id="Ipilimumab.Comment"><h4>Comment</h4><p>The clinical presentation 10 days after a third infusion of ipilimumab and approximately 90 days after starting therapy was typical of the hepatic injury from this monoclonal antibody. Despite discontinuing further infusions, the liver injury worsened and was eventually treated with low doses of corticosteroids, with a slow but eventually complete response.</p></div></div></div><div id="Ipilimumab.CASE_REPORTS_SUBMITTED_TO_LIV"><h2 id="_Ipilimumab_CASE_REPORTS_SUBMITTED_TO_LIV_">CASE REPORTS SUBMITTED TO LIVERTOX</h2><p>Clinical cases of drug-induced liver injury that have been submitted to LiverTox (<a href="https://livertox.niddk.nih.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">"Submit a Case Report"</a>) are available for review. Most of these reference cases are from the Drug-Induced Liver Injury Network, but others are from users of LiverTox who have submitted data from an actual clinical case. All cases have been reviewed and cleared of personal identifiers and a brief comment added by the LiverTox editors. Click on the following link to view the submitted case reports that have been made publically available.</p><p><a href="https://livertox.niddk.nih.gov/Home/ReferenceCases/ipilimumab" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><u>Submitted Cases on Ipilimumab</u></a></p></div><div id="Ipilimumab.PRODUCT_INFORMATION"><h2 id="_Ipilimumab_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Ipilimumab.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Ipilimumab &#x02013; Yervoy&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antineoplastic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?label=all&#x00026;query=Ipilimumab" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Ipilimumab.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Ipilimumab_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Ipilimumab.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548335/table/Ipilimumab.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ipilimumab.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Ipilimumab.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Ipilimumab.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Ipilimumab.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Ipilimumab.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Ipilimumab.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Ipilimumab</td><td headers="hd_h_Ipilimumab.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><b><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135287563" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">477202-00-9</a></b></td><td headers="hd_h_Ipilimumab.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Monoclonal Antibody</td><td headers="hd_h_Ipilimumab.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Not Available</td></tr></tbody></table></div></div></div><div id="Ipilimumab.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Ipilimumab_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 16 February 2018</p><p>Abbreviations: CTLA-4, cytotoxic T lymphocyte-associated antigen-4; PD-1, programmed cell death receptor-1.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Ipilimumab.R1">Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-54.<div><i>(Expert review of hepatotoxicity published in 1999; well before the availability of most monoclonal antibody therapies).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R2">Reuben A. Biological immunosuppressives. Hepatotoxicity of immunosuppressive drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 580-2.<div><i>(Review of hepatotoxicity of immunosuppressive agents; mentions that "the biological immunosuppressants are largely free from hepatotoxicity, with the exception of the TNF alpha antagonists"; ipilimumab is not specifically discussed).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R3">Chabner BA, Barnes J, Neal J, Olson E, Mujagiv H, Sequist L, Wilson W, et al. Targeted therapies: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1731-53.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R4">Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100: 8372-7.  [<a href="/pmc/articles/PMC166236/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC166236</span></a>] [<a href="/pubmed/12826605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12826605</span></a>]<div><i>(Initial study of anti-CTLA-4 therapy in 14 patients with melanoma, 6 of whom developed clinically apparent immune adverse reactions, including one with hepatitis arising after the third infusion [ALT 6820 U/L], resolving over the ensuing 4 months with corticosteroid therapy: Case 1).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R5">O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-7.  [<a href="/pubmed/20147741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20147741</span></a>]<div><i>(In a clinical trial of ipilimumab in 155 patients with metastatic melanoma, 109 patients [70%] suffered an immune related adverse event, including 14 [9%] with a liver related event, 2 of which were severe and 1 fatal).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R6">Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.  [<a href="/pmc/articles/PMC3549297/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3549297</span></a>] [<a href="/pubmed/20525992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20525992</span></a>]<div><i>(Controlled trial of ipilimumab vs a glycoprotein-100 vaccine vs both in 676 patients with metastatic melanoma from 125 centers in 13 countries found ipilimumab therapy prolonged median survival from 6.4 to 10.0 months, but that adverse events were common and usually immune mediated; ALT elevations [&#x0003e;5 times ULN] occurred in 0.5-0.8% of ipilimumab treated patients, but in none of controls).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R7">Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507.  [<a href="/pubmed/21074065" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21074065</span></a>]<div><i>(Review of immune related adverse events including hepatitis associated with ipilimumab therapy; recommends stopping therapy for grade 3 toxicity [ALT &#x0003e;5 times ULN] and initiating corticosteroids for at least 30 days).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R8">Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.  [<a href="/pubmed/21639810" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21639810</span></a>]<div><i>(Trial of ipilimumab and dacarbazine vs dacarbazine alone in 502 patients with metastatic melanoma found ALT elevations in 33% on the combination vs 6% on dacarbazine alone, and ALT values above 5 times ULN in 16% vs 0.7%, but no deaths due to liver failure).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R9">Ipilimumab (Yervoy) for metastatic melanoma. Med Lett Drugs Ther 2011; 53 (1367): 51-2.  [<a href="/pubmed/21701442" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21701442</span></a>]<div><i>(Concise review of the pharmacology, efficacy and safety of ipilimumab as therapy of metastatic melanoma shortly after its approval in the US; common side effects are diarrhea, nausea, fatigue, pruritus, rash and colitis; immune related side effects can include hepatitis; cost of a single dose averages $30,000).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R10">Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, Thompson J, Fulcher D, Kefford R. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011; 29: e237-40.  [<a href="/pubmed/21220617" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21220617</span></a>]<div><i>(61 year old man with melanoma developed fever and rash 10 days after a second dose of ipilimumab [bilirubin 1.2 mg/dL, ALT 2521 U/L, Alk P 275 U/L, ANA negative], rapidly improving on high doses of methylprednisolone, but relapsing when dose was reduced [bilirubin peak 3.8, ALT 6362 U/L], ultimately responding to addition of antithymocyte globulin and mycophenylate).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R11">Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48: 237-42.  [<a href="/pubmed/22030452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22030452</span></a>]<div><i>(Summary of safety and efficacy results of ipilimumab forming the basis of approval in Europe; ALT elevations were reported to occur in only 1-2% of patients, with onset of hepatic injury [which can be fatal] after 3-9 weeks).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R12">Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 2012; 57: 2233-40.  [<a href="/pmc/articles/PMC3792485/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3792485</span></a>] [<a href="/pubmed/22434096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22434096</span></a>]<div><i>(Clinical and histological features of 5 patients with liver injury due to ipilimumab; 3 men and 2 women, ages 43 to 76 years, arising after 2 to 4 courses, 39-71 days after initial dose [peak bilirubin 1.5-5.1 mg/dL, ALT 326-3070 U/L, Alk P 206-427 U/L], only one had autoantibodies, resolving with immunosuppressive therapy within 1-4 months; one had recurrence on rechallenge; liver biopsies showed acute hepatitis usually with prominent inflammation, interface hepatitis and confluent necrosis: Case 1).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R13">Weber JS, K&#x000e4;hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-7.  [<a href="/pubmed/22614989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22614989</span></a>]<div><i>(Review of the immune related adverse events associated with ipilimumab therapy and their management mentions that hepatotoxicity occurs in 3-9% of patients, usually with asymptomatic increases in ALT and bilirubin, but some with symptoms; authors recommend use of high doses of corticosteroids for 2 days followed by tapering doses to at least 30 days, multiple courses may be necessary and ipilimumab should not be restarted).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R14">Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-47.  [<a href="/pmc/articles/PMC3319861/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3319861</span></a>] [<a href="/pubmed/22271879" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22271879</span></a>]<div><i>(Among 177 patients with metastatic melanoma treated with ipilimumab, 33 had a long term objective response and 15 a complete response).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R15">Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the Ipilimumab Network. PLoS One 2013; 8: e53745.  [<a href="/pmc/articles/PMC3544906/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3544906</span></a>] [<a href="/pubmed/23341990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23341990</span></a>]<div><i>(Retrospective review of adverse reactions seen in 752 patients with metastatic melanoma treated with ipilimumab in 19 major cancer centers in Europe; 120 events were summarized including 11 involving the liver, which usually presented 3-6 weeks after starting therapy, with marked elevations in serum enzymes; one fatal case described in detail).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R16">Anderson L, Bhatia V. Ipilimumab immune-related adverse reactions: a case report. S D Med 2013; 66 (8): 315-7.  [<a href="/pubmed/24175496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24175496</span></a>]<div><i>(Abstract: a case of autoimmune hypophysitis during ipilimumab therapy).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R17">Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, Ibrahim N. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013; 31: 1071-7.  [<a href="/pubmed/23408334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23408334</span></a>]<div><i>(Six patients with ipilimumab hepatitis, ages 44-82 years, five men and one woman, treated with 2-4 cycles presenting with fatigue, fever and nausea [bilirubin 0.5-19.6 mg/dL, ALT 168-975 U/L], resolving within 34-147 days of stopping, many were treated with corticosteroids).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R18">Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-6.  [<a href="/pubmed/23550685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23550685</span></a>]<div><i>(In a pilot study of the combination of vemurafenib and ipilimumab in 10 patients with metastatic melanoma, serum ALT or AST elevations &#x02265;5 times ULN arose within 13-36 days of starting therapy in 6 patients, all of which were asymptomatic and reversible, which resolved within 4-12 days with corticosteroid therapy, recurring in one patient on restarting ipilimumab).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R19">Minter S, Willner I, Shirai K. Ipilimumab-induced hepatitis C viral suppression. J Clin Oncol 2013; 31: e307-8.  [<a href="/pubmed/23690418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23690418</span></a>]<div><i>(42 year old man with melanoma and chronic hepatitis C was treated with four courses of ipilimumab and had improvements in serum ALT [192 U/L to normal] and HCV RNA levels [398,938 to &#x0003c;12 IU/mL] during therapy that was partially sustained thereafter [ALT 39 U/L, HCV RNA 1558 IU/mL]).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R20">Bernardo SG, Moskalenko M, Pan M, Shah S, Sidhu HK, Sicular S, Harcharik S, et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 2013; 23: 47-54.  [<a href="/pubmed/23262440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23262440</span></a>]<div><i>(Among 11 patients with malignant melanoma treated with ipilimumab, 6 [54%] developed some degree of ALT elevation after 1 to 4 courses, but only one had values above 5 times ULN and all resolved with temporary delay in therapy).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R21">Weber JS, Dummer R, de Pril V, Lebb&#x000e9; C, Hodi FS; MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119: 1675-82.  [<a href="/pubmed/23400564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23400564</span></a>]<div><i>(In clinical trials of ipilimumab in 676 patients with melanoma, immune related adverse events occurred in ~60% of patients arising 3-9 weeks after starting and often mild, but severe in 12% and fatal in 1%, including one case of acute liver failure).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R22">Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18: 733-43.  [<a href="/pmc/articles/PMC4063401/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4063401</span></a>] [<a href="/pubmed/23774827" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23774827</span></a>]<div><i>(Thorough review of side effects of ipilimumab therapy of melanoma states that common adverse events include fatigue, nausea, vomiting, diarrhea, fever, headache, dizziness, rash and pruritus occurring in 70-88% of patients, and that hepatotoxicity occurs in 2-9% that can be self-limited, but also can be severe and require corticosteroid therapy).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R23">McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S; MDX010-20 Investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 2013; 24: 2694-8.  [<a href="/pubmed/23942774" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23942774</span></a>]<div><i>(Among 676 patients with melanoma enrolled in the phase III trial of ipilimumab, 94 [20%] survived for 2 years and 42 [16%] for 3 years; late onset immune related adverse events occurred in 11 patients [14%], but were usually mild and none were hepatic).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R24">Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014; 12: 116.  [<a href="/pmc/articles/PMC4030525/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4030525</span></a>] [<a href="/pubmed/24885479" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24885479</span></a>]<div><i>(Among 855 patients with melanoma treated with ipilimumab in an expanded access program, 19 [2%] developed "liver toxicity", which led to stopping therapy in 1 patient and death from hepatitis in another).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R25">Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-17.  [<a href="/pmc/articles/PMC5744258/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5744258</span></a>] [<a href="/pubmed/25891304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25891304</span></a>]<div><i>(Trial of ipilimumab with or without nivolumab in 142 patients with melanoma found higher rates of response but also side effects with the antibody combination, ALT elevations occurring in 22.3% vs 4.3% and values above 5 times ULN in 10.5% vs 0%, but there were no deaths from liver injury).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R26">Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-na&#x000ef;ve patients with metastatic uveal melanoma. PLoS One 2015; 10 (3): e0118564.  [<a href="/pmc/articles/PMC4356548/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4356548</span></a>] [<a href="/pubmed/25761109" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25761109</span></a>]<div><i>(Among 53 patients with metastatic uveal melanoma treated with ipilimumab, response rates were poor and side effects were common, ALT elevations occurred in 7% and were above 5 times ULN in 4%).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R27">Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014; 312: 1744-53.  [<a href="/pmc/articles/PMC4336189/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4336189</span></a>] [<a href="/pubmed/25369488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25369488</span></a>]<div><i>(Among 245 patients with metastatic melanoma treated with ipilimumab with or without sargramostim [GM-CSF] found improved objective responses with the combination and lower rates of severe adverse events, ALT elevations above 5 times ULN occurring in 5.1% vs 5.8% of patients).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R28">Ravi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA, Shirai K, et al. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer 2014; 2: 33.  [<a href="/pmc/articles/PMC4195895/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4195895</span></a>] [<a href="/pubmed/25317333" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25317333</span></a>]<div><i>(Among 9 patients with metastatic melanoma and either chronic hepatitis C [n=4] or B [n=5] treated with ipilimumab, viral levels and serum ALT levels did not change in a consistent manner; most with hepatitis B were on antiviral prophylaxis). </i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R29">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 49 cases were attributed to antineoplastic agents, one of which was due to ipilimumab).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R30">Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, et al.; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.  [<a href="/pubmed/25891173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25891173</span></a>]<div><i>(Among 834 patients with advance melanoma treated with pembrolizumab [Pem: 10mg/kg every 2 or 3 weeks] or ipilimumab [Ipil: 3 mg/kg every 3 weeks], 6 month progression free survival was higher with Pem [47% and 46%] than Ipil [26.5%] and adverse events were less; thyroiditis was more common with Pem, whereas colitis and hypophysitis were more common with Ipil; ALT elevations occurred in 3% [Pem] vs 3.5% [Ipil] and were above 5 times ULN in 0.2% vs 0.8%).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R31">Ahmed T, Pandey R, Shah B, Black J. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep 2015; 2015.  [<a href="/pmc/articles/PMC4513455/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4513455</span></a>] [<a href="/pubmed/26174726" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26174726</span></a>]<div><i>(50 year old woman with metastatic melanoma developed fever and liver test abnormalities after a first infusion of ipilimumab [bilirubin 0.9 rising to 1.8 mg/dL, ALT 640 to 4700 U/L, Alk P 366 to 604 U/L], treated with corticosteroids and then ATG and mycophenolate and resolving in 4 weeks, not restarted).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R32">Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, Doyle LA. Ipilimumab-associated Hepatitis: Clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 2015; 39: 1075-84.  [<a href="/pubmed/26034866" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26034866</span></a>]<div><i>(Among 11 patients with metastatic melanoma treated with ipilimumab who developed liver injury and had liver biopsy, age range 33-71 years, 10 men, arising after 1-4 doses, all with ALT elevations and 3 with jaundice [bilirubin 0.7 to 15.6 mg/dL, ALT 185 to 3075, Alk P 48 to 453 U/L], 9 biopsies showed panlobular or central hepatitis, one showed NASH, one cholangitis; all resolved in 2-12 weeks with corticosteroid therapy).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R33">Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer 2015; 3: 22.  [<a href="/pmc/articles/PMC4469313/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4469313</span></a>] [<a href="/pubmed/26082835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26082835</span></a>]<div><i>(67 year old man with liver transplant for hepatitis C developed metastatic melanoma treated with 4 doses of ipilimumab and 2 weeks later had ALT elevations without jaundice that resolved without corticosteroids or antirejection therapy).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R34">Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190-209.  [<a href="/pubmed/27085692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27085692</span></a>]<div><i>(Review of the major immune mediated side effects of anti-PD-1 therapy, with characteristics of 11 cases of hepatitis due to pembrolizumab or nivolumab, arising 1-4 weeks after initial infusions, resolving mostly with corticosteroid therapy and stopping drugs).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R35">Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 2016; 21: 1230-40.  [<a href="/pmc/articles/PMC5061539/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5061539</span></a>] [<a href="/pubmed/27401894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27401894</span></a>]<div><i>(Review of immune mediated adverse events from anti-PD-1 therapy and their management; ALT elevations are reported in 2-4% of patients with higher rates with combinations; recommend stopping therapy if ALT elevations are above 5 times ULN or bilirubin is raised and use of methylprednisolone, but merely delay in therapy and increased frequency of monitoring if ALT elevations are above 3 times but below 5 times ULN).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R36">Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 2016; 4: 13.  [<a href="/pmc/articles/PMC4791920/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4791920</span></a>] [<a href="/pubmed/26981243" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26981243</span></a>]<div><i> (35 year old woman with refractory metastatic melanoma received 4 infusions of ipilimumab and 4 cyclces of nivolumab with partial response only and death, autopsy showing necrotic melanoma metastases and CD8+ T cell infiltrates in many organs, including liver).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R37">Sp&#x000e4;nkuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C, Amaral T. Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins. Eur J Cancer 2017; 81: 203-5.  [<a href="/pubmed/28641200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28641200</span></a>]<div><i> (49 year old woman with metastatic melanoma developed abdominal pain after 3 cycles of ipilimumab and nivolumab [bilirubin 5.5 mg/dL, ALT 722 U/L, Alk P 449 U/L], responding slowly to methylprednisolone and ATG, and then tolerating pembrolizumab therapy without recurrence).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R38">Yildirim S, Deniz K, Do&#x0011f;an E, Ba&#x0015f;kol M, G&#x000fc;rsoy &#x0015e;, &#x000d6;zkan M. Ipilimumab-associated cholestatic hepatitis: a case report and literature review. Melanoma Res 2017; 27: 380-2.  [<a href="/pubmed/28489679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28489679</span></a>]<div><i>(45 year old man with refractory metastatic melanoma developed jaundice 7 days after a 4th dose of ipilimumab [bilirubin 8.5 mg/dL, ALT 96 U/L, Alk P 678 U/L, GGT 1320 U/L], resolving slowly with corticosteroid therapy).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R39">Tanaka R, Fujisawa Y, Sae I, Maruyama H, Ito S, Hasegawa N, Sekine I, et al. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Jpn J Clin Oncol 2017; 47: 175-8.  [<a href="/pubmed/28173241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28173241</span></a>]<div><i>(59 year old man with refractory metasatic melanoma treated with 11 doses of nivolumab developed severe hepatitis after one dose of ipilimumab with fever, chills and fatigue [bilirubin 2.1 rising to 12.6 mg/dL, ALT 1623 U/L, Alk P 1306 U/L, INR 1.45], eventually improving with high doses of methylprednisolone and mycophenolate).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R40">Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res 2017; 27: 271-3.  [<a href="/pubmed/28146044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28146044</span></a>]<div><i> (46 year old man with refractory metastatic melanoma developed fever, rash and liver test abnormalities while receiving ipilimumab and nivolumab, but also 1 week after a course of levofloxacin [bilirubin and Alk P not given, ALT 116 U/L, eosinophils 1400/uL], resolving with corticosteroid therapy and stopping monoclonal antibodies).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R41">Bunchorntavakul C, Reddy KR. Drug hepatotoxicity: newer agents. Clin Liver Dis 2017; 21: 115-34.  [<a href="/pubmed/27842767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27842767</span></a>]<div><i> (Review of hepatotoxicity of agents newly approved for use in the US including ipilimumab which is associated with ALT elevations in 3-9% of patients [above 5 times ULN in 0.5% to 1.5%], most of which are self-limited in course; however, clinically apparent, largely hepatocellular, injury can also occur, especially when combined with dacarbazine or vemurafenib, usually responding to corticosteroid therapy, but rare deaths from hepatic failure have been reported).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R42">Everett J, Srivastava A, Misdraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol 2017; 41: 134-7.  [<a href="/pubmed/27792061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27792061</span></a>]<div><i>(Fibrin ring granulomas were found in liver biopsies from 2 patients with metastatic melanoma treated with ipilimumab who developed fever, rash and elevated liver tests after 3 infusions [bilirubin 0.5 and 0.2 mg/dL, ALT 130 and 643 U/L, Alk P 264 and 70 U/L], resolving with corticosteroid therapy).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R43">Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, et al.; CheckMate 238 Collaborators. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824-35.  [<a href="/pubmed/28891423" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28891423</span></a>]<div><i> (Among 905 patients with malignant melanoma after surgical resection given adjuvant therapy for at least 18 months, progression free survival was less with ipilimumab than nivolumab [60.8% vs 70.5% at 12 months] and side effects were greater [serious adverse events in 43% vs 18%] including ALT elevations [15% vs 6% which were above 5 times ULN in 5.7% vs 1.1%]).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R44">Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol 2018; 41 (8): 760-5.  [<a href="/pubmed/28749795" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28749795</span></a>]<div><i> (Among 218 pateints treated with various checkpoint inhibitors at the Mayo Clinic over a 5 year period, 17 developed hepatotoxicity [12 after ipilimumab alone], with onset after median of 52 days [16-151 days] and resolving mostly with corticosteroid therapy after 31 days [6-56 days]).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R45">Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, et al. Acute liver graft rejection after ipilimumab therapy. Ann Oncol 2017; 28: 2619-20.  [<a href="/pubmed/28961840" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28961840</span></a>]<div><i> (67 year old woman with ocular melanoma underwent liver transplantation and later had metastases to graft, developed liver test abnormalities 3 weeks after stopping immunosuppression [sirolimus and mycophenolate] and receiving one infusion of ipilimumab [ALT 750 U/L], biopsy showing acute rejection).</i></div></div></li><li><div class="bk_ref" id="Ipilimumab.R46">Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 2018 Feb 5. [Epub ahead of print]  [<a href="/pubmed/29403081" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29403081</span></a>]<div><i> (Liver histology in 7 cases of hepatotoxicity from checkpoint inhibitors [2 ipilimumab, 7 nivolumab] showed lobular hepatitis with prominence of CD8+ lymphocytes in most, with less eosinophilic infiltration and bile plugs than typical drug induced hepatitis and less plasma cell infiltration and portal inflammation than autoimmune hepatitis).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548335</span><span class="label">PMID: <a href="/pubmed/31643657" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643657</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/InterleukinRcptAntag/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ipratropium/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548335&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548335/?report=reader">PubReader</a></li><li><a href="/books/NBK548335/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548335" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548335" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Ipilimumab. [Updated 2018 Feb 16].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548335/pdf/Bookshelf_NBK548335.pdf">PDF version of this page</a> (135K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Ipilimumab+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Ipilimumab: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Ipilimumab" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Ipilimumab: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4860088" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4860088" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4860088" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27116334" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Safety of immune checkpoint inhibitors in Chinese patients with melanoma.</a><span class="source">[Melanoma Res. 2016]</span><div class="brieflinkpop offscreen_noflow">Safety of immune checkpoint inhibitors in Chinese patients with melanoma.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wen X, Wang Y, Ding Y, Li D, Li J, Guo Y, Peng R, Zhao J, Zhang X, Zhang XS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Melanoma Res. 2016 Jun; 26(3):284-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25823918" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.</a><span class="source">[Clin Ther. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mahoney KM, Freeman GJ, McDermott DF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Ther. 2015 Apr 1; 37(4):764-82. Epub 2015 Mar 29.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31273167" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Clinical Significance of Ipilimumab and the Combination Therapy as Immune Checkpoint Inhibitor].</a><span class="source">[Gan To Kagaku Ryoho. 2019]</span><div class="brieflinkpop offscreen_noflow">[Clinical Significance of Ipilimumab and the Combination Therapy as Immune Checkpoint Inhibitor].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Muto Y, Kitano S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Gan To Kagaku Ryoho. 2019 Jun; 46(6):1011-1015. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28648699" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.</a><span class="source">[Eur J Cancer. 2017]</span><div class="brieflinkpop offscreen_noflow">Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Heppt MV, Heinzerling L, Khler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Cancer. 2017 Sep; 82:56-65. Epub 2017 Jun 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25619164" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.</a><span class="source">[Cancer Med. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Camacho LH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cancer Med. 2015 May; 4(5):661-72. Epub 2015 Jan 25.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643657" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643657" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:18:34-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal105&amp;ncbi_phid=CE8C400E0465FB3100000000086E026D&amp;ncbi_session=CE8C400E04686981_2158SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548335%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548335&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548335/&amp;ncbi_pagename=Ipilimumab - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C400E04686981_2158SID /projects/books/PBooks@9.2 portal105 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>